Methods for diagnosis of and predicting treatment efficacy of hormone receptor expressing tumors, cancers and neoplasias

Abstract

The invention relates to diagnosis, detection, screening, identifying and predicting methods. In various embodiments, methods of the invention include diagnosis, detection, or screening for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject; identifying a subject that will or is likely to respond to a therapy for a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia); and predicting therapeutic efficacy of a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) treatment in a subject.

What is claimed: 
     
       1. A method of analyzing a prostate, ovarian, breast or endometrial sample, the method comprising:
 (a) contacting the prostate, ovarian, breast or endometrial sample from a subject, with a hormone polypeptide or hormone polypeptide analog that binds to LHRH- or hCG/LH receptors under conditions allowing the hormone or hormone analog to bind the LHRH- or hCG/LH receptors; 
 (b) determining an amount of LHRH- or hCG/LH receptors in the sample by detecting the amount of hormone polypeptide or hormone polypeptide analog that is bound to the LHRH- or hCG/LH receptors in the sample; 
 (c) contacting cells obtained from the sample with a peptide comprising the cytotoxic sequence KFAKFAKKFAKFAKKFAKQHWSYGLRPG (SEQ ID NO: 1); and 
 (d) after the contacting of (c), determining the IC 50  value according to a sensitivity of the cells to SEQ ID NO:1, wherein the IC 50  value is 5.5 μM or less and wherein greater LHRH- or hCG/LH receptor expression indicates increased sensitivity of the cells. 
 
     
     
       2. The method of  claim 1 , comprising identifying a sample according to the determining of (b), wherein greater than 50% of the cells express LHRH- or hCG/LH receptors. 
     
     
       3. The method of  claim 1 , wherein the cytotoxic sequence is biotin-conjugated. 
     
     
       4. The method of  claim 1 , wherein the hormone polypeptide or hormone polypeptide analog comprises one or more D-amino acids. 
     
     
       5. The method of  claim 1 , wherein the hormone polypeptide or hormone polypeptide analog is biotin-conjugated.